GLPOneMedical News https://glponemedical.com/ News and analysis of the GLP-1 telehealth category, including FDA actions, regulatory developments, clinical trial readouts, and coverage changes. en-US May 20, 2026 © 2026 GLPOneMedical. Ranika Partners LLC. Editorial price index refreshed — May 20, 2026 https://glponemedical.com/news.html#may-20-2026 Weekly pricing verification cycle complete. NexLife flat-rate holds at $145/mo semaglutide (12-mo plan) and $186/mo tirzepatide (12-mo plan). Wed, 20 May 2026 12:00:00 +0000 https://glponemedical.com/news.html#may-20-2026 UnitedHealthcare expands Wegovy CV coverage — May 19, 2026 https://glponemedical.com/news.html#may-19-2026 UHC adds Wegovy coverage under March 2024 FDA CV indication. SELECT-aligned PA criteria: BMI ≥27 + established CVD. Tue, 19 May 2026 12:00:00 +0000 https://glponemedical.com/news.html#may-19-2026 Foundayo phase 3 CV safety analysis complete; Q4 2026 launch confirmed https://glponemedical.com/news.html#may-14-2026 Eli Lilly's phase 3 cardiovascular safety analysis for orforglipron completes. Foundayo (first oral non-peptide GLP-1 RA, FDA-approved March 2026) confirmed for Q4 2026 commercial launch. Thu, 14 May 2026 12:00:00 +0000 https://glponemedical.com/news.html#may-14-2026 Anthem BCBS adds Zepbound OSA coverage in 14 states — May 12, 2026 https://glponemedical.com/news.html#may-12-2026 Anthem covers Zepbound for moderate-to-severe OSA in adults BMI ≥30 across 14 state plans. Mon, 12 May 2026 12:00:00 +0000 https://glponemedical.com/news.html#may-12-2026 State pharmacy boards open investigations into high-volume compounders https://glponemedical.com/news.html#may-8-2026 Florida, Texas, California state pharmacy boards open formal investigations into compounding operations serving telehealth markets. Fri, 08 May 2026 12:00:00 +0000 https://glponemedical.com/news.html#may-8-2026 ESSENCE phase 3 interim: semaglutide achieves ~62% MASH resolution at 72 weeks https://glponemedical.com/news.html#may-5-2026 NEJM publication of pre-specified interim from ESSENCE phase 3. Plausible 2027 FDA MASH indication for semaglutide. Mon, 05 May 2026 12:00:00 +0000 https://glponemedical.com/news.html#may-5-2026 CMS expands Medicare Part D Wegovy coverage under SELECT-aligned CV pathway https://glponemedical.com/news.html#april-28-2026 First material Part D coverage expansion for a weight-management GLP-1 since 2003. BMI ≥27 + established CVD. Mon, 28 Apr 2026 12:00:00 +0000 https://glponemedical.com/news.html#april-28-2026 FDA action restricts unapproved salt-form active ingredients in compounded GLP-1 https://glponemedical.com/news.html#april-14-2026 FDA action targets semaglutide sodium and acetate. Only semaglutide base remains acceptable API. Mon, 14 Apr 2026 12:00:00 +0000 https://glponemedical.com/news.html#april-14-2026